Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6267-6276

  Ribas, Antoni ^a,b,f   Comin Anduix, Begoña ^a   Chmielowski, Bartosz ^a   Jalil, Jason ^a   De La Rocha, Pilar ^a   McCannel, Tara A ^c   Ochoa, Maria Teresa ^a   Seja, Elizabeth ^a   Villanueva, Arturo ^a   Oseguera, Denise K ^a   Straatsma, Bradley R ^c   Cochran, Alistair J ^a,b   Glaspy, John A ^a,b   Hui, Liu ^d   Marincola, Francesco M ^d   Wang, Ena ^d   Economou, James S ^a,b   Gomez Navarro, Jesus ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JULES STEIN EYE INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^f UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; MELAN A; TICILIMUMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOPHYSITIS; MALE; MELANOMA; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS;

EID: 70349680756     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1254     Document Type: Article

References (46)

1. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-594
2. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736
3. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a CTL associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007;12:873-883
4. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23: 8968-8977 (Pubitemid 46217464)
5. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of Tremelimumab in patients with metastaticmelanoma. J Clin Oncol 2009;27:1075-1081
6. Comin-Anduix B, Gualberto A, Glaspy JA, et al. Definition of an immunologicresponse using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res 2006;12:107-116 (Pubitemid 43166183)
7. Comin-Anduix B, Lee Y, Jalil J, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008;6:22. (Pubitemid 351803824)
8. Ribas A, Comin-Anduix B, Economou JS, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 2009;15:390-399
9. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180: 347-352 (Pubitemid 24181083)
10. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-685 (Pubitemid 29289432)
11. Valmori D, Dutoit V, Lienard D, et al. Tetramerguided analysis of TCR β-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanomapatients. JImmunol 2000;165:533-538 (Pubitemid 30429548)
12. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendriticc ells [see comments]. Nat Med 1998;4:328-332 (Pubitemid 28144092)
13. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologicand therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastaticmelano ma [see comments]. Nat Med 1998;4:321-327
14. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendriticc ell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003; 9:998-1008. (Pubitemid 36323703)
15. Ribas A, Glaspy JA, Lee Y, et al. Role of dendriticc ell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004;27:354-367 (Pubitemid 39121924)
16. Tchekmedyian S, Glasby J, Korman A, Keler T, Deo Y, Davis T. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. ProcA m SocClin Oncol Proc ASCO 2002;21:56.
17. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003;24:58-61. (Pubitemid 36120639)
18. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358:155-157
19. Gordon LK, Ribas A, Nusinowitz S, et al. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendriticc ells for metastaticmelanom a. Control Clin Trials 2004;25: 400-407 (Pubitemid 39013975)
20. Straatsma BR, Nusinowitz S, Young TA, et al. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastaticmela noma. Am J Ophthalmol 2007;143:958-969 (Pubitemid 46764658)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [see comments]. J Natl Cancer Inst 2000;92:205-216 (Pubitemid 30099779)
22. Jaeger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162-169 (Pubitemid 26248194)
23. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide- loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-1288 (Pubitemid 34564330)
24. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000;18:457-459 (Pubitemid 30217539)
25. Wang E. RNA amplification for successful gene profiling analysis. J Transl Med 2005;3:28. (Pubitemid 41522079)
26. Simon R, Lam A, Li MC, Ngan M, Menenzes A, Zhao Y. Analysis of Gene Expression Data Using BRB-Array Tools. Cancer Inform 2007;2:11-17 (Pubitemid 47075796)
27. Jin P, Zhao Y, Ngalame Y, et al. Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics 2004;5:55. (Pubitemid 39546662)
28. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868 (Pubitemid 29003722)
29. Hamid O, Solomon JC, Scotland R, et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 2007;13:215-222 (Pubitemid 46121871)
30. Hodi FS, Hoos A, Ibrahim R, et al. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol 2008;26:abstr 3008.
31. Ribas A, Antonia S, Sosman J, et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. ASCO Annual Meeting Proceedings 2007;25:8523.
32. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide or dacarbazine) in patients with advanced melanoma. J Clin Oncol 2008;26:abstr LBA9011.
33. Gattinoni L, Ranganathan A, Surman DR, et al. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood 2006;108:3818-3823 (Pubitemid 44864564)
34. Lurquin C, Lethe B, De Plaen E, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005;201:249-257 (Pubitemid 40189434)
35. Sosman JA, Carrillo C, Urba WJ, et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 2008;26:2292-2298
36. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006;313:1972-1975 (Pubitemid 44498006)
37. Romani N, Reider D, Heuer M, et al. Generation of mature dendriticc ells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196: 137-151 (Pubitemid 26306735)
38. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-3142 (Pubitemid 28018007)
39. Schuler-Thurner B, Dieckmann D, Keikavoussi P, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000;165:3492-3496 (Pubitemid 30728209)
40. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendriticc ells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17: 563-570
41. Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendriticc ells loaded with allogeneictumor lysate to metastaticm elanoma patients. J Immunother 2008; 31:101-112 (Pubitemid 351619409)
42. Panelli MC, Wang E, Phan G, et al. Geneexpression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemicIL -2 administration. Genome Biol 2002;3:RESEARCH0035.
43. Panelli MC, Stashower ME, Slade HB, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007;8:R8.
44. Butterfield LH, Disis ML, Fox BA, et al. A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on Immunotherapy Biomarkers". J Transl Med 2008;6:81.
45. Yuan J, GnjaticS, Li H, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008;105:20410-20415
46. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69:609-615